GE Healthcare Receives FDA Clearance on Anesthesia Therapy

by Barbara Kram, Editor | October 15, 2007

* Helps prevent over-pressure of the lungs, while helping to avoid alveoli collapse. 1
* Supports the filling of even the stiff alveoli early in the inspiratory cycle giving the maximum time for gas exchange. 2
* Provides better oxygenation at lower peak airway pressures. 3

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

During traditional pressure control ventilation, volumes delivered to the patient can vary widely. Volume control ventilation delivers a consistent tidal volume, but may not ventilate the stiff alveoli until late in the inspiratory time. PCV-VG mode solves this dilemma and brings the best of both modes to the operating room.

LOGIQ e highlights:
The LOGIQ e launched in 2006; now the LOGIQ e Breakthrough 2008 features enhancements to image clarity, system simplicity and system efficiency. GE partnered with anesthesiologists to develop a customized, streamlined offering designed specifically for anesthesia applications.

"GE is committed to breakthroughs in anesthesia care to enhance critical patient care and to expand the performance of our integrated perioperative systems," said Hannu Syrjala, General Manager of GE Healthcare's Life Support Solutions business. "The breadth of GE's leadership allows for the convergence of technologies in anesthesia care, such as our laptop-style, miniaturized ultrasound system designed for the operating room."
References:

1. Hospital Physician, January 2006, Page 20 Kanagarajan & Oropella, Mt Sinai Medical Center, NYC
2. Critical Care Medicine Tutorials, University of Pennsylvania, Patrick Neligan, 2007
3 Journal of Trauma, November 1996 41 (5) 8008-14 Branson, Campbell and Porembka

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Back to HCB News